INTRODUCTION
Since the identification of Hageman factor in 1958 (1) a great deal has been learned concerning its role in the coagulation, kinin-forming, and fibrinolytic systems of This is publication no. 1025 from the Scripps Clinic and Research Foundation.
Received for publication 2 September 1975 and in revised form 9 December 1975. plasma. Until recently, however, information concerning the molecular structure of the protein has been sparse and sometimes conflicting (2) (3) (4) (5) (6) . The confusion has been undoubtedly due, in part, to the multiple forms of the enzymatically active Hageman factor moiety that result from differing purification and manipulatory techniques used by various investigators. In addition, there is little understanding of the portions of the molecule that do not have enzymtic activity, although such regions may have other important functions.
In the studies reported here, we have combined the use of radiolabeled Hageman factor, functional assays of activity, and immunologic techniques to probe the structure of the native Hageman factor molecule. In a previous report (5) the cleavage of the native molecule into three fragments by various enzymes was documented. This report further details the participation of these regions in the two known biologic activities of Hageman factor, namely enzymatic activity on various substrates and the ability to bind to negative surfaces. For the former, we studied the action of the various regions on prekallikrein (presumably the active site is the same for the activity on the three known substrates, although other portions of the molecule may influence the enzyme-substrate interaction) and as a model of surface binding we chose to study the interaction of the regions with kaolin. METHODS Plasma proteins. Human Hageman factor was purified and labeled with 'I as described previously (5) . The preparation used contained 1.05 mg Hageman factor (determined by quantitative radial immunodiffusion assays) per mg protein (measured by Kjeldahl nitrogen determination). Prekallikrein was prepared from human plasma by techniques previously published (5) with the following modifications: elution from the DEAE-Sephadex column was effected in a single step with 0.01 M phosphate buffer + 0.06 M NaCl pH 7.7. After dialysis against 0.01 M phosphate + 0.1 M NaCl pH 6.0 the prekallikrein was applied to a column of carboxymethyl-Sephadex C-50 and washed with this buffer until no further protein eluted. A linear salt gradient of 0.1-0.25 M NaCl was used to remove the prekallikrein. The prekallikrein-containing fractions were then passed over Sepharose 4B beads (Pharmacia Fine Chemicals, Inc., Piscataway, N. J.) to which soybean trypsin inhibitor (Sigma Chemical Co., St. Louis, Mo.) was covalently coupled to remove any traces of active kallikrein. Contaminating proteins present at this point were identified as fi2-glycoprotein I and -y-globulin. The presence of plasminogen activator was not assayed. The prekallikrein was concentrated by negative pressure before use. Activation to kallikrein was accomplished by incubation of 50 01 prekallikrein with 50 pAl suspended Enzite agarose trypsin beads (Miles Laboratories, Elkhart, Ind.) for 60 min at 220C. After removal of the beads by centrifugation, the kallikrein activity was assayed by incubation of 10 dul enzyme (75 ,gg total protein) with 1.5 ml of 1 mM benzoyl-L-arginine ethyl ester (BAEe) ' at 370C. Hydrolysis was found to occur at a rate of 0.33 tM BAEe/min per mg protein.
Partially purified rabbit prekallikrein, used for assays of Hageman factor, was prepared as previously described (7) being used after the second DEAE-Sephadex column at a concentration of 12.5 Ag/ml (1,000 mU2). The 28,000 mol wt fragment was isolated by preparative polyacrylamide-gel electrophoresis from a highly concentrated pool of Hageman factor (approximately 600 ,ug/ml Hageman factor, 3.3 mg/ml total protein) which had undergone partial spontaneous fragmentation during 2 mo of storage at 40C. 2 ml of the sample was applied to a rectangular gel of 20 ml of 7% acrylamide, and electrophoresis was carried out in the cold at 200 V for 5 h using a Tris-glycine pH 8.6 buffer system. The gel was sectioned into 38 slices, and each slice was eluted into 2 ml Tris-buffered saline. Assays of the eluates for their prekallikrein-activating ability yielded a strong, sharp peak in the anodal region. Further analysis showed this to be the 28,000 mol wt prekallikrein activator derived from Hageman factor.
Antibody to Hageman factor. Goat antibody to human Hageman factor was prepared and absorbed as previously described (5) . For use in immunoelectrophoresis, the absorbed antiserum was diluted 1: 10.
Assay of Hageman factor activity. Enzymatic activity of Hageman factor or its fragments was determined by its ability to convert prekallikrein to kallikrein. Rabbit prekallikrein, known to be activated by human as well as rabbit Hageman factor (4) , was employed at a concentration of 100 mU (1.25 /Lg)/0.1 ml. In general, the sample to be tested was added at neutral pH in a volume not exceeding 0.2 ml-100 mU/0.1 ml rabbit prekallikrein in plastic tubes. After incubation at 37°C for 20 min, 1.5 or 3.0 ml of 1 mM BAEe was added to each tube. Absorbance at 253 nm was measured at various times after the addition of BAEe, an increase with time indicating the presence of kallikrein.
Sodium dodecyl sulfate (SDS)-acrylamide gel electrophoresis. Electrophoresis in 7% polyacrylamide gels containing 0.1%o SDS was performed according to the method 1Abbreviations used in this paper: BAEe, benzoyl-L-ar ginine ethyl ester; PBS, phosphate-buffered saline; SDS, sodium dodecyl sulfate.
21 U of kallikrein activity is that amount of enzyme which when added to 3 ml of 1 mM BAEe causes hydrolysis of 1 ,mol/min at 37°C. FIGURE 1 Double immunodiffusion in agar showing the separation of anti-Hageman factor antibody into two noncross-reacting fractions. Trypsin-treated Hageman factor was incubated with kaolin (see text for details) and separated into two pools based on ability to bind to kaolin. Separate aliquots of anti-Hageman factor were absorbed with either the kaolin-bound Hageman factor fragments or fragments not bound to kaolin which remain in the supernate. 10 ul of the following were placed in the wells as num- Immunoelectrophoresis. Immunoelectrophoresis based on the method of Grabar and Williams (9) as modified by Scheidegger (10) was performed in 1% agarose at a current of 40 V/plate for 75 min. Immunoprecipitation was allowed to occur for 18 h followed by 24-48 h of washing in phosphate-buffered saline (PBS), drying, and staining of the slides with Amido-Schwartz. Photographic reproductions of faint precipitin bands reported in this paper are augmented by line drawings where necessary.
Preparation of antibodies to specific portions of the Hageman factor molecule. Antibodies specific to portions of the Hageman factor molecule were prepared by absorption of whole antiserum with isolated portions of the enzymatically treated Hageman factor molecule as follows: partially purified human Hageman factor was concentrated by lyophilization to a concentration of approximately 720 ,ug/1.2 ml to which 50 Al containing 2.5 ,ug of 'I-labeled Hageman factor (0.94 /ACi/ug) was added. 1 ml was incubated with 1 ,ug trypsin (an amount calculated to give complete cleavage) for 30 min at 370C followed by the addition of 250 lug/25 /Al ovomucoid trypsin inhibitor. 0.5 ml of the trypsin-treated material was incubated with 5 mg kaolin for 60 min at 220C with shaking. After removal of the supernate following a 3-min centrifugation at 3,400 rpm, the kaolin was washed twice with 0.5 ml PBS. The radioactivity content of the initial supernate and the washed kaolin was determined. The supernate was sequentially absorbed with fresh 5-mg aliquots of kaolin until no more counts were removed. This was found to require four absorptions. 0.2 ml of monospecific antihuman Hageman factor was absorbed with either 50 pl of the fourth supernate or 2.5 mg of the kaolin used for the first absorption. The two resulting antibodies (Table I) . To activate and cleave the Hageman factor, 175 Al was then incubated with 0.5 Ag trypsin for 20 min at 370C followed by a blocking of the trypsin with 50 Ag ovomucoid trypsin inhibitor. That activation of the Hageman factor had occurred was confirmed by BAEe hydrolysis after incubation of 5 Al of the trypsin-treated material with 100 mU rabbit prekallikrein for 20 min at 370C (Table I ). This activation was accompanied by a cleavage of the 80,000 mol wt molecule into fragments of 52,000, 40,000, and 28,000 mol wt as determined by an examination of the radioactivity pattern obtained when 20 Al was subjected to electrophoresis in acrylamide gels containing 0.1% SDS (Fig. 2 , bottom panel). To determine which fragment(s) were capable of binding to a negatively charged surface, 90 Al of the trypsin-treated Hageman factor was incubated with 1.5 mg kaolin for 20 min at 220C. The supernate (containing 31% of the radioactive counts added) was removed after a brief centrifugation and the kaolin was washed several times with buffer. SDS was added to a final concentration of 0.1% to 50 Al of the supernate and a suspension containing 500 Ag of the washed kaolin. The samples were then applied to SDS acrylamide gels. (Greater than 90% of the radioactivity bound to the kaolin is removed during the electrophoresis.) The results, shown in the middle and top panels of Fig. 2 , show only the 28,000 mol wt fragment remaining in the supernate while the 52,000, 40,000, and residual 80,000 moieties were bound to the kaolin. Prekallikreinactivating activity was found only in the supernate (Table I).
Further evidence that the prekallikrein-activating capacity found in the supernate described above was indeed associated with the 28,000 mol wt fragment was obtained by subjecting duplicate 8-l samples of the supernate material to electrophoresis in agarose on a microscope slide for 75 min. One section of the plate was then developed with anti-Hageman factor antibody placed in a trough alongside the electrophoresis path, and the other portion of the plate was sectioned into 2-mm segments and allowed to elute overnight into 0.1 ml PBS. The eluates were counted for radioactivity and assayed for their capacity to activate prekallikrein. As shown in Fig. 3 After separation of the supernate by centrifugation, 10 1l of it was subjected to SDS-polyacrylamide gel electrophoresis with the resultant profile shown in the top panel. After washing, the kaolin precipitate was layered on top of an SDS-polyacrylamide gel and the pattern shown in the bottom panel was obtained.
appeared with the incubation with normal plasma but not with the plasma of the hereditary angioneurotic edema patient. The same shift was seen when purified Cl inhibitor (kindly supplied by Dr. Peter Harpel) was preincubated with the 28,000 fragment. Development of similar plates containing normal human plasma with anti-Cl inhibitor revealed migration of this protein occurred coincidentally with the new, cathodally migrating 28,000 fragment after it was mixed with normal plasma.
Characterization of various regions of the Hageman factor molecule by their immunologic and electrophoretic properties. The single polypeptide chain of human Hageman factor, previously shown to be enzymatically cleaved at two primary sites (5), was divided into three regions based on these two cleavage points. As diagrammed in Fig. 7 , the region resulting in a 40,000 mol wt fragment and incubated at 370C for 10 min. 10 A of each mixture plus a control of 28,000 fragment alone were placed in separate wells cut in a layer of agarose on a microscope slide. Electrophoresis was carried out for 75 min after which troughs were cut and filled with a 1: 10 dilution of a stock monospecific anti-human Hageman factor antibody. After 24 h the plate was washed, dried, and stained with the results shown in Fig. 6 Fig. 7 shows three bands, one in each of the three migratory positions developing with antibody to the e region and two migrating in the ,-and a-globulin regions, appearing with anti-c antibody. The band between cde and anti-c is prevented from forming by the faster diffusing 'The choice of the letters c, d, and e to designate the various regions of the human Hageman factor molecule was arbitrary. The use of the letter a to designate one region was eliminated due to the potential confusion with the symbol HFa which is commonly used to designate an active form of Hageman factor. ' The designation cde will be used here although it is equally possible that analysis of the terminal amino acids of the fragments will show the actual order to be edc. fragment c, which is first to precipitate the anti-c antibody in this region.
To determine which visible precipitin band corresponded with which of the five definable Hageman factor species known to result from interaction with enzymes, the Hageman factor was subjected to preparative polyacrylamide gel electrophoresis as described in Methods in an attempt to isolate the various fragments. After 5 h of electrophoresis, the block was sliced into 38 segments and each slice was eluted into 2 ml Tris-buffered saline. Immunoelectrophoresis was then performed on various eluates using the anti-c and anti-e antibodies in addition to the anti-Hageman factor (cde). Only the e fragment, found in the anodal eluates, was fully separated from the other fragments. It appeared in immunoelectrophoresis in the albumin-migrating position with either anti-Hageman factor (cde) or anti-e, giving no band with anti-c antibody (see Fig. 6 ). The other fragments were all found in overlapping peaks in the top (cathodal) half of the block. The eluate of the seventh slice from HF fragments anti-HF (cde) HF fragments I kanlin abserptien FIGURE 10 Immunoelectrophoretic pattern of a solution of Hageman factor (HF) fragments before and after being absorbed with kaolin. 100 ju of a solution of highly concentrated, partially cleaved Hageman factor (HF fragments) was incubated with 1 mg of kaolin for 60 min at 22°C with shaking, followed by centrifugation and removal of the supernate. 10 g1 of the supernate material and 10 "I of the mixture before absorption were subjected to electrophoresis for 75 min at 40 V in 1% agarose. The slide was developed with antibody to Hageman factor [anti-HF (cde) ]. The anode is to the right.
Relationship of Structure and Function in Hageman Factor 857 the cathodal end (fx 7) is shown in Fig. 9 as an example of the type of pattern obtained and the identification of the fragment positions which could be determined. The eluate gave one band in the f-position and two bands in the a-position with anti-Hageman factor (cde). The fl-migrating molecule did not react with anti-e, thereby eliminating the possibility of it representing the cde (whole Hageman factor molecule), de, or e fragment, and implying that it was either the c or cd fragment. Of the two bands in the a-region, one reacted with anti-c and not with anti-e, and the other gave a precipitin arc with anti-e and not anti-c. Both of these bands disappeared if the fraction was treated with trypsin before immunoelectrophoresis (bottom panel, Fig. 9 ), and only two bands, one in the fl-region and the other in the albumin location, appeared. Since it is known (5) that complete trypsin degradation yields the c (40,000 mol wt) and e (28,000 mol wt) fragments (an intact d fragment of 12,000 mol wt has never been observed after enzymatic cleavage) and the e has been shown to be the albumin-migrating protein, it can be concluded that the c fragment migrates in the P-region. Immunoelectrophoresis of whole plasma in agarose shows the intact Hageman factor molecule (cde) also migrates in the slow f-region. Since only two bands are seen in the fl-region when the electrophoresed fragments are precipitated with anti-Hageman factor (cde), the cd and de fragments must account for the two a-bands. Fraction 7, therefore, must contain fragments c, cd, and de. Based on such data from the individual fractions, we were able to identify the five precipitin bands as designated in Fig. 7 .
The ability of the fraction eluates to activate prekallikrein was tested, and in each case such a capacity was noted wherever the e region of the molecule was present (i.e., if the fraction contained cde, de, or e). The capacity of various fragments to bind to negative surfaces was determined by immunoelectrophoresis before and after incubation with kaolin. The results of such an incubation are shown in Fig. 10 . The c, cd, and de fragments, and the whole molecule cde, are removed from the solution by the kaolin; only the e fragment remains unbound.
DISCUSSION
The 80,000 mol wt Hageman factor molecule can be divided into three regions based on the fragments obtained after enzymatic treatment. Enzymatic cleavage of the molecule occurs during activation of Hageman factor in fluid phase by kallikrein, plasmin, clotting Factor XI, and perhaps other enzymes. The fragments of Hageman factor were shown previously (5) to be of 40,000, 12,000, and 28,000 mol wt. The Hageman factor molecule with its cleavage fragments is shown in the upper panel of Fig. 7 . The ability of the regions to bind to surfaces was first determined by incubating radiolabeled fragments with kaolin and examining by SDS-acrylamide gel electrophoresis which ones became bound. By this means it was determined that the 52,000 and 40,000 mol wt fragments, as well as the 80,000 mol wt native molecule, were able to bind, while the 28,000 mol wt fragment remained in the supernate. Conversely, when the whole molecule was first bound to the kaolin and then a proteolytic enzyme was added, cleavage occurred with the 28,000 mol wt fragment being released from the surface. From these data one can conclude that the 28,000 mol wt fragment of the molecule, designated region e, does not contain sites capable of binding to a negatively charged surface. The observation that this region is released into the supernate when kaolin-bound Hageman factor is incubated with kallikrein or prekallikrein bears interesting implications in the interpretation of studies of surface activation performed in the presence of such enzymes (i.e., in whole plasma). It will be important to ascertain the amount and rate of release of the enzymatically active 28,000 mol wt fragment from a surface in the presence of whole plasma and the rate of inhibition of activated Hageman factor both bound to the surface and free in the supernate after release.
The cleavage of surface-bound Hageman factor observed with plasma could be caused by several enzymes: kallikrein (5, 11), plasmin (5, 12) , and Factor XI (5) have all been shown to cleave Hageman factor. It was of great interest to note that in the presence of normal plasma, the 28,000 fragment appeared to be bound to a protein of 110,000 mol wt, yielding a peak of radiolabel at approximately 140,000 mol wt. Immunoelectrophoresis of the fragment with normal or hereditary angioneurotic edema (Cl inhibitor-deficient) plasma suggests that the fragment is binding to C1 esterase inhibitor. A complex of C1 inhibitor and the e fragment would correlate with the 140,000 mol wt peak of radiolabel observed in the SDS studies. Inhibition of Hageman factor activity by Cl esterase inhibitor was first reported by Forbes et region changed the properties (mol wt and electrophoretic mobility) of both. It could represent a region of the native molecule which is rapidly broken down into small polypeptide pieces when initially separated from the larger c and e regions, rendering it nonantigenic in immunoelectrophoresis and undetectable on SDS-acrylamide gels. The facts that one never detects a de fragment (having a mol wt of 40,000) in the supernate after enzymatic cleavage of radiolabeled fragments on kaolin, and the removal of the de fragment (as determined either by radiolabel or immunoelectrophoresis) from the supernate after kaolin absorption of the fragments leads one to the conclusion, however, that there is a "kaolin-binding" site located in the d region when it is attached to the e, since the e region itself is clearly not able to bind to kaolin. The characteristics of the native Hageman factor molecule and the five fragments one can isolate after selective proteolytic cleavage are given in Table II .
When highly concentrated partially cleaved Hageman factor solutions were subjected to immunoelectrophoresis, heterogeneity in the albumin-migrating band could often be seen (see Figs. 7 and 10) . Whether this represents various configurations of the e fragment, genetic heterogeneity, or actual multiple forms of the polypeptide is unclear. It should be noted that multiple prealbumin bands have been observed on polyacrylamide gel electrophoresis after enzymatic cleavage of Hageman factor (3, 4, 12) .
Other investigators have previously reported evidence of different forms of Hageman factor-derived molecules in clotted serum (3, 15) or glass-activated plasma fractions (12) , with the capacity to activate prekallikrein although the exact nature of these forms was not determined. It is clear from the studies reported here that cleavage of the native Hageman factor molecule by kallikrein or plasmin, both of which might be present in serum, could give rise to two smaller molecular weight molecules (de and e) containing the enzymatically active region. Kaplan and Austen (3, 12) showed the conversion of one intermediate form of Hageman factor to a smaller, prealbumin molecule as well as an additional intermediate which cannot be directly accounted for by the model presented here. Presumably, action by other serum proteases on the molecule may give rise to other, as yet unknown, cleavage patterns. Bagdasarian et al. (16) have also reported molecules of differing molecular weights capable of activating prekallikrein and suggested that these may be derived from Factor XII by limited proteolysis.
The localization of the sites on the Hageman factor molecule responsible for the binding to surfaces and the enzymatic activity on substrates to unique, separable regions will undoubtedly aid in future studies of the exact nature of "contact activation." Studies to determine the amino acid sequence around the active site are being undertaken. Further investigation into the primary, secondary, and tertiary structure necessary to cause the molecule to bind and become active will be of great im- 
